What TV doesn't, print can't; we deliver.
What TV doesn't, print can't; we deliver.
Phase III trials (as a 2-dose regimen) were conducted for safety, immunogenicity in ~3100 subjects, in 14 trial sites across India.
Bharat Biotech International Limited (BBIL), a global leader in vaccine innovation and developer of vaccines for infectious diseases, on Wednesday announced its rotavirus oral vaccine ROTAVAC® has been introduced by Nigeria to immunize its children
